Trinity Capital Provides $12M Growth Funding to Delphinus Medical Technologies in Novi

Materialise, a 3-D printing company and provider of personalized medical solutions, is working to accelerate the delivery of patient-specific medical implants in the United States, with the opening of a new 3-D printing facility in Plymouth Township.
169
Novi’s Delphinus Medical Technologies received $12 million in funding from Trinity Capital to help the company make its SoftVue breast screening technology available on a larger scale. // Photo courtesy of Delphinus

Trinity Capital Inc. in Arizona, a provider of capital to growth-stage companies, has committed $12 million to Delphinus Medical Technologies Inc. in Novi, so that the company can scale up its SoftVue system and make it available to more medical facilities.

Delphinus, a medical imaging company, developed SoftVue, a dense breast screening method that increases cancer detection and decreases unnecessary call backs, while delivering a more comfortable patient experience.

The SoftVue 3D Whole Breast Ultrasound Tomography System was approved by the U.S. Food & Drug Administration (FDA) in October of 2021. This technology improves the standards for early breast cancer detection and patient comfort, with 95 percent of women who have experienced SoftVue indicating they would recommend the exam to other women, the company states.

Delphinus continues to expand its commercial foundation and most recently added Corewell Health as a commercial site to build a dense breast screening program to benefit patients.

“We are excited to be a part of Delphinus’ journey as they innovate life-saving medical imaging technology,” says Lauren Cosentino, managing director, life sciences at Trinity. “We believe in their team and are excited to help accelerate their growth trajectory.”

The growth capital should enable the team at Delphinus to continue to scale operations and broaden their impact in the global health care community.

“Mammography is not enough to address the screening needs of dense breast patients,” says Mark J. Forchette, president and CEO of Delphinus Medical Technologies. “The addition of SoftVue for dense breast screening implements a comprehensive solution for sites to transform the clinical experience of their patients.”